

Kyprolis® (carfilzomib) for Injection and Blinatumomab

Pablo Cagnoni
Onyx President

AMGEN®
Pioneering science delivers vital medicines™

AMGEN®

Pioneering science delivers vital medicines™

Kyprolis® (carfilzomib) for Injection

Significant Unmet Need Remains In Multiple Myeloma

Relative Survival by Cancer Type



Sources: SEER, Cancer Facts & Figures 2014, American Cancer Society, 2014

Provided October 28, 2014, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

AMGEN®

Global Myeloma Market to Double by 2020

Global Market

($B)



Source: EvaluatePharma, September 2014, Decision Resources MM Pharmacor

Provided October 28, 2014, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

AMGEN®

Quarterly Sales Are Increasing

2014 YTD Sales: $240M

($M)



~ 14,000 Patients Have Received Kyprolis® Commercially

- **Strong quarter-over-quarter growth**
- **Current indication based on Phase 2 single-arm data**

AMGEN®

Duration of Therapy Is Longer In Earlier Lines



Key Drivers for Growth

- Earlier treatment (smoldering, asymptomatic)
- Increase duration of therapy
- Reduce patient drop-off and increase number of patients by line
- Number of lines will increase as new therapies extend survival and more treatment options are needed

Source: Onyx market research

Provided October 28, 2014, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

Efficacy Remains Primary Driver of Treatment Choice

Importance of Decision Drivers for Usage In Multiple Myeloma



Source: Physician Treatment Goals Qual, January 2014

Provided October 28, 2014, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

- **Depth of response is evolving to become an important driver of treatment choice**
  - **Emergence of stringent complete response (sCR) and minimal residual disease (MRD) as goals**
- **Kyprolis® provides physicians the ability to achieve deep and durable responses**

AMGEN®

The Future of Myeloma Treatment

Today

Complete Response



SPEP



IFE

Tomorrow

Minimal Residual Disease



Flow Cytometry



Molecular Profiling Assays

Future

Redefine Goal of Therapy

- **Transform myeloma into a chronic, manageable disease**
- **Cure subset of patients**

MRD: Depth of Response Impacts Outcome In Myeloma



J Clin Oncol. Vol 31, No 20, July 10, 2013

SPEP = simple protein electrophoresis; IFE = immuno-fixation

AMGEN

ASPIRE Topline Results Support Expansion Into Relapsed Myeloma

Kyprolis® + Revlimid® + Low-Dose Dexamethasone (KRd) vs Revlimid® + Low-Dose Dexamethasone (Rd)

- **Progression-free survival primary endpoint successfully met at interim analysis**
  - **Hazard ratio = 0.690 (95% CI: 0.570–0.834) *P* < 0.0001**
  - **8.7 month difference in median PFS: 26.3 months in KRd arm vs 17.6 months in Rd arm**
- **Overall survival secondary endpoint data are not yet mature**
  - **Trend in favor of KRd that did not reach statistical significance**
- **Safety profile consistent with the current US Kyprolis® label, including rate of cardiac events**
- **Treatment discontinuation due to adverse events and on-study deaths were comparable between the two arms**
- **No new safety signals identified**

Results support hypothesis that Kyprolis® represents best-in-class proteasome inhibitor

AMGEN®

ASPIRE: Unprecedented PFS In Relapsed Myeloma With KRd

Phase 3 Studies Performed Across Relapsed Myeloma



***Time to progression endpoint; similar approximation to PFS**

Provided October 28, 2014, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

AMGEN

Substantial Opportunity for Kyprolis® In Relapsed Myeloma



ASPIRE	Reason to Believe
Increase duration of therapy in second line	ASPIRE designed to treat patients with Kyprolis® for 18 months
Increase number of patients treated in second line	Effective, new option available in relapsed multiple myeloma
Increase second-line share	Physicians and patients believe in importance of depth and duration of response

Source: Onyx market research

Provided October 28, 2014, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

AMGEN®

Majority of Treatment Opportunities In Earlier Lines of Therapy

Study	Objectives
Head-to-Head Phase 3s Second Line: ENDEAVOR Kd First Line: CLARION KMP First Line: ECOG KRd	• Establish superiority to Velcade® • Establish Kyprolis® in early lines • Further improve efficacy profile with higher dose
CHAMPION Phase 2 Weekly Kd	• Improve convenience • Establish high dose weekly • ORR = 81% in Phase 1 • Phase 2 enrollment complete
Weekly Phase 3 Weekly Kd	• Planning Phase 3 study

MRD analyses ongoing in Onyx-sponsored trials

KMP = Kyprolis® + melphalan-prednisone; Kd = Kyprolis® + dexamethasone

AMGEN®

Comprehensive Development Program to Establish Kyprolis® as Backbone of Therapy



Source: Clinicaltrials.gov

POM = Pomalyst®; IXA = ixazomib; mAb = monoclonal antibody

AMGEN®

Considerable Interest In Combining Kyprolis® With Novel Agents

Company Collaborations	Investigator-Sponsored Trials
GlaxoSmithKline: Afuresertib: Phase 1, Phase 2	SANOFI: SAR650984: Phase 2b
pharmacyclics: Ibrutinib: Phase 1/2	Karyopharm Therapeutics: Selinexor: Phase 1b
ARRAY BIOPHARMA: Filanesib: Phase 2	ARRAY BIOPHARMA: Filanesib: Phase 1/2

More than 50 investigator-sponsored studies with Kyprolis®

Provided October 28, 2014, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

AMGEN®

AMGEN®

Pioneering science delivers vital medicines™

Oprozomib

Oprozomib: An Oral Proteasome Inhibitor

- Highly active drug
- New stepped-up dosing
- Optimized formulation
- Improved GI tolerability

Trial	Phase 1	Phase 2
Hematologic malignancies, including Waldenström's macroglobulinemia		
Relapsed and refractory multiple myeloma (OPOMd)		

GI = gastrointestinal; OPOMd = oprozomib + Pomalyst®-dexamethasone

AMGEN®

AMGEN®

Pioneering science delivers vital medicines™

Blinatumomab

ALL Incidence In US and EU

ALL Incident Case Count (2012)



Breakdown by Geography

Total ALL Patients	5,134	4,078
Adult ALL	2,359 *(46% of ALL)*	2,077 *(51% of ALL)*
Adult B-Precursor ALL	2,080	1,831
Adult Ph-Negative B-precursor ALL (First Line)	1,601	1,410
Adult Relapsed/Refractory Ph-Negative B-precursor ALL	1,107 *(47% of Adult ALL)*	949 *(46% of Adult ALL)*

ALL = acute lymphoblastic leukemia; Ph- = Philadelphia negative
Source: SEER database; Amgen research

AMGEN

Addressing Unique Needs of ALL Patients

Leverage Onyx Expertise and Infrastructure In Hematology/Oncology

ONYX 360™ PHARMACEUTICALS

- **Connect** patients to additional resources
  - Lodging
  - Transportation
  - Psychosocial
- **Manage** shifts between sites of care
- **Infusion Assistance**
- **Co-pay Assistance**
- **Free Product Assistance**
- **Reimbursement Support**
- **Clinical Information**



Provided October 28, 2014, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

AMGEN®

Establish Blinatumomab In Adult R/R ALL and Develop Next Indications and Formulations



2021+ — Expand with additional indications into other B-cell malignancies

2017–2021 — Develop new formulations/mode of administration

2017–2019 — Broaden blinatumomab use in ALL

2015–2016 — Establish blinatumomab in ALL with initial launch* in adult Philadelphia-negative R/R ALL

R/R = relapsed/refractory
*Following FDA approval

Provided October 28, 2014, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

AMGEN